EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Lacticaseibacillus paracasei GM-080 Ameliorates Allergic Airway Inflammation in Children with Allergic Rhinitis: From an Animal Model to a Double-Blind, Randomized, Placebo-Controlled Trial

En-Kwang Lin, Wen-Wei Chang iD, Jhih-Hua Jhong iD, Wan-Hua Tsai, Chia-Hsuan Chou, I-Jen Wang iD

Cells · 28.02.2023 · 12 (5) · 768

DOI: 10.3390/cells12050768 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cells, online erschienen am 28.02.2023. Verfasst von En-Kwang Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan. Hauptthemen laut MEDLINE: Lacticaseibacillus paracasei, Respiratory Hypersensitivity, Rhinitis, Allergic. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, GenMont Biotech (Taiwan).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Probiotics may facilitate the clinical management of allergic diseases. However, their effects on allergic rhinitis (AR) remain unclear. We examined the efficacy and safety of Lacticaseibacillus paracasei GM-080 in a mouse model of airway hyper-responsiveness (AHR) and in children with perennial AR (PAR) by using a double-blind, prospective, randomized, placebo-controlled design.

Methods

The production of interferon (IFN)-γ and interleukin (IL)-12 was measured by using an enzyme-linked immunosorbent assay. GM-080 safety was evaluated via the whole-genome sequencing (WGS) of virulence genes. An ovalbumin (OVA)-induced AHR mouse model was constructed, and lung inflammation was evaluated by measuring the infiltrating leukocyte content of bronchoalveolar lavage fluid. A clinical trial was conducted with 122 children with PAR who were randomized to receive different doses of GM-080 or the placebo for 3 months, and their AHR symptom severity scores, total nasal symptom scores (TNSSs), and Investigator Global Assessment Scale scores were examined.

Results

Among the tested L. paracasei strains, GM-080 induced the highest IFN-γ and IL-12 levels in mouse splenocytes. WGS analysis revealed the absence of virulence factors or antibiotic-resistance genes in GM-080. The oral administration of GM-080 at 1 × 107 colony forming units (CFU)/mouse/day for 8 weeks alleviated OVA-induced AHR and reduced airway inflammation in mice. In children with PAR, the oral consumption of GM-080 at 2 × 109 CFU/day for 3 months ameliorated sneezing and improved Investigator Global Assessment Scale scores significantly. GM-080 consumption led to a nonsignificant decrease in TNSS and also nonsignificantly reduced IgE but increased INF-γ levels.

Conclusion

GM-080 may be used as a nutrient supplement to alleviate airway allergic inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacticaseibacillus paracaseiRespiratory HypersensitivityRhinitis, AllergicAnimalsMiceDisease Models, AnimalInflammationLacticaseibacillusProspective StudiesHumansChildDouble-Blind Method

Stichwörter der Autor:innen

allergic airway inflammationallergic rhinitisanimal modelclinical trialprobiotics

Autor:innen und Institutionen

  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.
  • Division of Colorectal Surgery, Department of Surgery, Wanfang Hospital, Taipei Medical University, Taipei 110301, Taiwan.
  • School of Biomedical Sciences, Chung Shan Medical University, Taichung 402306, Taiwan.
  • Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402306, Taiwan.
  • Department of Medical Research, Hsinchu MacKay Memorial Hospital, Hsinchu 300044, Taiwan.
  • Research and Development Department, GenMont Biotech Incorporation, Tainan 741014, Taiwan.

ORCID-Profile: Wen-Wei Chang, Jhih-Hua Jhong, I-Jen Wang

Förderung

  • Ministry of Science and Technology
  • GenMont Biotech (Taiwan)

Zitieren

APA

Lin, E. K., Chang, W. W., Jhong, J. H., Tsai, W. H., Chou, C. H., & Wang, I. J. (2023). Lacticaseibacillus paracasei GM-080 Ameliorates Allergic Airway Inflammation in Children with Allergic Rhinitis: From an Animal Model to a Double-Blind, Randomized, Placebo-Controlled Trial. Cells, 12(5), 768. https://doi.org/10.3390/cells12050768

Vancouver

Lin EK, Chang WW, Jhong JH, Tsai WH, Chou CH, Wang IJ. Lacticaseibacillus paracasei GM-080 Ameliorates Allergic Airway Inflammation in Children with Allergic Rhinitis: From an Animal Model to a Double-Blind, Randomized, Placebo-Controlled Trial. Cells. 2023;12(5):768. doi:10.3390/cells12050768

BibTeX
@article{Lin2023,
  author = {Lin, En-Kwang and Chang, Wen-Wei and Jhong, Jhih-Hua and Tsai, Wan-Hua and Chou, Chia-Hsuan and Wang, I-Jen},
  title = {Lacticaseibacillus paracasei GM-080 Ameliorates Allergic Airway Inflammation in Children with Allergic Rhinitis: From an Animal Model to a Double-Blind, Randomized, Placebo-Controlled Trial},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {5},
  pages = {768},
  doi = {10.3390/cells12050768}
}
Kostenlos starten →